Communiqués Adial Pharmaceuticals, Inc.

Actions

ADIL

US00688A3041

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 18/08/2026			Varia. 5j.	Varia. 1 janv.
5,450 ^USD	+9,22%		+29,45%	-0,91%

14/08	Adial Pharmaceuticals, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
16/06	Adial Pharmaceuticals clôture une première tranche de financement de 32 millions de dollars	MT

Communiqués

17/08	Adial Pharmaceuticals Reports 2026 Second Quarter Financial Results and Provides Business Update	AQ
16/06	Adial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE Financing	AQ
11/06	Adial Pharmaceuticals Announces Acquisition of Azora Therapeutics and up to $64 Million Financing	AQ
11/05	Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update	AQ
29/04	Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045	AQ
27/04	Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program	AQ
22/04	Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial	AQ
24/03	Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans	AQ
06/03	Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update	AQ
04/03	Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe	AQ
03/03	Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement	AQ
24/02	Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement	AQ
23/02	Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One	AQ
17/02	Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference	AQ
04/02	Adial Applauds Congressional Directive Advancing Alternative Clinical Trial Endpoints for Substance Use Disorders, Strengthening Regulatory Path for AD04	AQ
03/02	Adial Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price Requirement	AQ
14/01	Adial Pharmaceuticals Announces Publication of International PCT Patent Application to Protect Core Assets and Extend IP Exclusivity to at least 2045	AQ
26/11	Adial Pharmaceuticals Announces a Warrant Inducement Transaction for Approximately $2.86 Million in Gross Proceeds	AQ
17/11	Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
14/11	Adial Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update	AQ
17/10/25	Adial Pharmaceuticals CEO was a Featured Guest on The Big Biz Show	AQ
09/10/25	Adial Pharmaceuticals Partners with Genomind for Precision Medicine Testing Solution	AQ
16/09/25	Adial Pharmaceuticals Provides Business Update Following Favorable Comments from FDA End-of-Phase 2 (EOP2) Meeting for AD04	AQ
03/09/25	Adial Pharmaceuticals Granted a 180 Calendar Day Extension by Nasdaq to Regain Compliance with the Minimum Bid Price Rule	AQ
20/08/25	Adial Pharmaceuticals Encouraged By U.S. Senate Support for Expanded Clinical Trial Endpoints Beyond Abstinence in Alcohol and Substance Use Disorder Treatments	AQ